Shots:

• The second P-III LIBRETTO-531 involves assessing of selpercatinib vs physician's choice of cabozantinib or vandetanib in 400 patients in ratio (2:1) with advanced or metastatic RET-mutant MTC who have received no prior systemic therapy for metastatic disease
• The study will have efficacy endpoints as progression-free survival (PFS)- treatment failure-free survival (TFFS)- overall survival (OS)- overall response rate (ORR)- and duration of response (DoR)
• LOXO-292 is an oral investigational new medicine targeted to inhibit native RET signaling as well as anticipated acquired resistance mechanisms and has also received Breakthrough Therapy designation in RET fusion-positive NSCLC- RET-mutant medullary thyroid cancer (MTC) and RET fusion-positive thyroid cancers

Click here to read full press release/ article

Ref: PRNewswire | Image: Eli Lilly